Dietary Supplementation With NAD+-Boosting Compounds in Humans: Current Knowledge and Future Directions

Simple item page
Author(s)Freeberg, Kaitlin A.
Author(s)Udovich, Ce Ann C.
Author(s)Martens, Christopher R.
Author(s)Seals, Douglas R.
Author(s)Craighead, Daniel H.
Date Accessioned2023-07-07T14:19:13Z
Date Available2023-07-07T14:19:13Z
Publication Date2023-05-05
DescriptionThis is a pre-copyedited, author-produced version of an article accepted for publication in The Journals of Gerontology: Series A following peer review. The version of record Kaitlin A Freeberg, MS and others, Dietary Supplementation With NAD+-Boosting Compounds in Humans: Current Knowledge and Future Directions, The Journals of Gerontology: Series A, 2023;, glad106, https://doi.org/10.1093/gerona/glad106 is available online https://doi.org/10.1093/gerona/glad106. © The Author(s) 2023. Published by Oxford University Press on behalf of The Gerontological Society of America. All rights reserved. This article will be embargoed until 05/05/2024.
AbstractAdvancing age and many disease states are associated with declines in nicotinamide adenine dinucleotide (NAD+) levels. Preclinical studies suggest that boosting NAD+ abundance with precursor compounds, such as nicotinamide riboside or nicotinamide mononucleotide, has profound effects on physiological function in models of aging and disease. Translation of these compounds for oral supplementation in humans has been increasingly studied within the last 10 years; however, the clinical evidence that raising NAD+ concentrations can improve physiological function is unclear. The goal of this review was to synthesize the published literature on the effects of chronic oral supplementation with NAD+ precursors on healthy aging and age-related chronic diseases. We identified nicotinamide riboside, nicotinamide riboside co-administered with pterostilbene, and nicotinamide mononucleotide as the most common candidates in investigations of NAD+-boosting compounds for improving physiological function in humans. Studies have been performed in generally healthy midlife and older adults, adults with cardiometabolic disease risk factors such as overweight and obesity, and numerous patient populations. Supplementation with these compounds is safe, tolerable, and can increase the abundance of NAD+ and related metabolites in multiple tissues. Dosing regimens and study durations vary greatly across interventions, and small sample sizes limit data interpretation of physiological outcomes. Limitations are identified and future research directions are suggested to further our understanding of the potential efficacy of NAD+-boosting compounds for improving physiological function and extending human health span.
SponsorThis work was supported by the National Institutes of Health (F31HL154782 to K.A.F., K01AG054731 to C.R.M., R01AG061514 to D.R.S., and K01HL153326 to D.H.C.).
CitationKaitlin A Freeberg, MS and others, Dietary Supplementation With NAD+-Boosting Compounds in Humans: Current Knowledge and Future Directions, The Journals of Gerontology: Series A, 2023;, glad106, https://doi.org/10.1093/gerona/glad106
ISSN1758-535X
URLhttps://udspace.udel.edu/handle/19716/32973
Languageen_US
PublisherThe Journals of Gerontology: Series A
Keywordsclinical trials
Keywordsnicotinamide riboside
Keywordsnutrition
Keywordsphysiology
Keywordssuccessful aging
TitleDietary Supplementation With NAD+-Boosting Compounds in Humans: Current Knowledge and Future Directions
TypeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Dietary supplementation with NAD.pdf
Size:
2.64 MB
Format:
Adobe Portable Document Format
Description:
Main article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.22 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Open Access Publications